IQVIA is a world leader in analytics and clinical research in the life sciences sector. Formed from a merger between IMS Health and Quintiles, it has over 40 years of experience in the sector, growing to become one of the world’s largest contract research organisations, with a network spanning more than 100 countries.
Since its founding, IQVIA has outperformed the market and is focusing on expanding biosimilar firms such as Humira. Humira provides generic drugs from existing medications without needing further data analysis. However, IQVIA’s involvement in new areas of research is likely to offset this trend.
With global medicine spending on track to reach £1.3 trillion by 2025, IQVIA is focusing its efforts on oncology and immunology, the most profitable sectors in pharmaceutical development. It is also building out its technological infrastructure, with a particular focus on artificial intelligence. While it is frank about the limitations of this technology within the sector, it greatly augments the data-handling capabilities of health science teams. Development in this sector is key to IQVIA’s growth plans for 2025 and beyond, which is on track with 2023-24 seeing a massive increase in company share value.
Kirsty
Company Specialist at Welcome to the Jungle
